Does Medicaid cover Wegovy?

Navigating insurance coverage for weight-loss medications like Wegovy, Ozempic, and Mounjaro can feel like solving a puzzle with constantly moving pieces. If you’re wondering whether your insurance will cover these popular GLP-1 medications—or what to do if it won’t—you’re not alone. With prices exceeding $1,000 per month without coverage, understanding your options is crucial for making weight management affordable and accessible.

The short answer: It depends. Coverage varies dramatically based on your insurance type, the specific medication, and why you need it. Let’s break down everything you need to know.

Understanding GLP-1 Medications: Different Drugs, Different Coverage Rules

Before diving into insurance specifics, it’s important to understand that Wegovy, Ozempic, and Mounjaro are not interchangeable in the eyes of insurance companies—even though they’re closely related medications.

Wegovy (semaglutide) is FDA-approved specifically for chronic weight management in adults with obesity (BMI ≥30) or overweight adults (BMI ≥27) with at least one weight-related condition. Because it’s labeled as a weight-loss drug, it faces significant coverage barriers.

Ozempic (also semaglutide, same active ingredient as Wegovy) is FDA-approved only for Type 2 diabetes management. Many insurers cover Ozempic for diabetes patients but will deny claims when it’s prescribed off-label for weight loss—even though the medication works the same way.

Mounjaro (tirzepatide) is similarly approved for Type 2 diabetes. Its sister drug, Zepbound, uses the same active ingredient but is approved for weight management. Like Ozempic, Mounjaro gets better insurance coverage when prescribed for its approved diabetes indication.

This distinction matters because your diagnosis directly impacts coverage. A diabetes patient typically faces fewer hurdles getting Ozempic or Mounjaro covered than someone seeking Wegovy purely for weight management.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

Commercial Insurance Coverage: The Good, the Bad, and the Prior Authorization

What Most Private Insurance Plans Cover

If you have commercial insurance through your employer or the ACA marketplace, here’s the general landscape:

For Type 2 Diabetes:

• Ozempic and Mounjaro are widely covered as essential diabetes treatments
• Typically placed in Tier 3 (non-preferred brand) or Tier 4 (specialty)
• Most plans require prior authorization to confirm your diabetes diagnosis
• You may need to demonstrate that first-line treatments (like metformin) haven’t adequately controlled your blood sugar

For Weight Management:

• Coverage for Wegovy is limited and inconsistent
• Many employer plans exclude anti-obesity medications entirely as ‘optional’ benefits due to high costs
• Plans that do cover Wegovy impose strict criteria and oversight
• Expect to pay significantly higher copays or coinsurance (often 20-40% after deductible)

The Prior Authorization Maze

Nearly all insurers require prior authorization (PA) for GLP-1 medications, especially for weight loss. Here’s what you’ll typically need to demonstrate:

Medical Necessity Criteria:

• BMI of 30 or higher (or BMI 27+ with at least one weight-related comorbidity like hypertension, sleep apnea, or prediabetes)
• Documentation of at least 6 months of supervised diet and lifestyle modification attempts that didn’t achieve adequate weight loss
• Confirmation that you don’t have contraindications (like personal/family history of medullary thyroid carcinoma)
• Some plans require proof you’ve tried and failed on older, cheaper weight-loss medications first

Step Therapy Requirements:Many insurers implement step therapy, meaning you must:

• Try less expensive interventions first (nutritional counseling, exercise programs)
• For diabetes patients: demonstrate inadequate control on standard medications before accessing GLP-1s
• Document your response to treatment with regular weight checks and follow-ups

Ongoing Approval:Even if initially approved, most plans require re-authorization every 3-6 months. You’ll need to show you’re:

• Achieving meaningful weight loss (typically ≥5% of baseline body weight)
• Attending follow-up appointments
• Adhering to lifestyle modifications

The PA process typically takes 5-7 business days for initial decisions, though appeals can extend to several weeks.

Common Denial Reasons (and How to Overcome Them)

Understanding why claims get denied helps you prepare stronger documentation upfront:

1. Insufficient Documentation: Missing records of supervised weight-loss attempts are the most common culprit. Keep detailed records from your provider documenting diet counseling, exercise plans, and weight measurements over time.

2. Not Meeting BMI Thresholds: Ensure your BMI is accurately calculated and documented. If you’re borderline, document your weight-related comorbidities thoroughly.

3. Plan Exclusions: Some employer plans categorically exclude weight-loss drugs. Check your Summary of Benefits or contact your HR department before pursuing authorization.

4. Off-Label Use: Requesting Ozempic or Mounjaro specifically for weight loss (when you don’t have diabetes) will trigger denials, as insurers only cover FDA-approved indications.

5. Missing Step Therapy: Skipping required prior treatments can lead to automatic denials. Work with your provider to document why alternatives aren’t appropriate or haven’t worked.

If You’re Denied:Don’t give up. Submit an appeal with:

• A detailed letter of medical necessity from your provider
• Complete documentation of your weight history and previous interventions
• Evidence of weight-related health conditions
• Scientific literature supporting the treatment

Studies suggest that a significant percentage of initial denials are overturned on first appeal when patients truly meet clinical criteria.

Medicare Coverage: Limited and Complicated

The Federal Exclusion:By law, Medicare Part D cannot cover medications used solely for weight loss. This means traditional Medicare won’t pay for Wegovy when prescribed for obesity management, regardless of medical necessity.

Important Exception:In 2024, Medicare began covering Wegovy for a specific cardiovascular indication: reducing risk of heart attack, stroke, and cardiovascular death in adults with established cardiovascular disease and obesity. If you have both obesity and documented heart disease, you may qualify for coverage under this narrower approval.

What Medicare Does Cover:

• Ozempic and Mounjaro for Type 2 diabetes (standard Part D coverage with typical copays)
• Prior authorization requirements vary by plan
• Usually placed in higher tiers with specialty drug cost-sharing

Medicare Advantage Plans:Some MA plans have begun offering limited obesity medication coverage as a supplemental benefit (not required under traditional Medicare rules). Coverage varies widely by plan and region, so check your specific MA plan’s formulary if you’re considering these medications.

Medicaid Coverage: A State-by-State Patchwork

Medicaid coverage for GLP-1 weight-loss drugs is perhaps the most complicated landscape, as states decide individually whether to cover anti-obesity medications. As of late 2025, only about 13 states provide any Medicaid coverage for drugs like Wegovy—and that number is shrinking due to budget pressures.

State-Specific Coverage Snapshot

California:Medi-Cal offered limited Wegovy coverage through 2025 with strict prior authorization (BMI ≥30 or ≥27 with comorbidities, 6-month supervised diet required). However, California is eliminating coverage for all GLP-1 weight-loss medications for adults effective January 1, 2026 due to budget constraints. Pediatric patients may still access coverage under EPSDT (Early and Periodic Screening, Diagnostic, and Treatment) provisions.

Texas:Texas Medicaid does not cover any obesity medications for adults (age 21+). The state exercises the federal option to exclude weight-loss drugs from its formulary. Patients under 21 may request case-by-case exceptions through EPSDT.

Florida:Florida Medicaid similarly excludes all weight-loss medications from coverage, including Wegovy, Saxenda, and related drugs. Only GLP-1s approved for diabetes (like Ozempic) are covered, and only for their FDA-approved diabetes indication.

New York:New York’s Medicaid program does cover Wegovy with prior authorization. Criteria mirror FDA guidelines: BMI ≥30 or ≥27 with comorbidities, documented lifestyle modification, and age ≥18. Quantity limits apply (typically 4 pens per 28 days).

Pennsylvania:Pennsylvania Medicaid added Wegovy coverage in 2023 with comprehensive PA criteria (BMI requirements, documented weight-related conditions, lifestyle attempts). Patients with diabetes must try diabetes-specific GLP-1s first. However, Pennsylvania is also discontinuing coverage for GLP-1 weight-loss medications in January 2026 due to rising costs.

Illinois:Illinois Medicaid does not cover obesity medications as of 2025. While the state expanded coverage for state employees in 2023, this did not extend to Medicaid beneficiaries.

Medicaid Coverage Trends

The trend is concerning for patients: states are rolling back obesity drug coverage despite clinical evidence of effectiveness. California and Pennsylvania’s 2026 eliminations reflect the budget reality—these medications cost states tens of millions annually. If you have Medicaid, verify your state’s current policy, as coverage is fluid and often subject to legislative budget cycles.

EPSDT Exception:Children and young adults under 21 on Medicaid may access medications through EPSDT even in states that don’t cover obesity drugs for adults. This federal requirement mandates coverage of medically necessary treatments for minors, creating a coverage pathway in otherwise restrictive states.

What to Do If Insurance Won’t Cover Your GLP-1 Medication

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer significant assistance for patients struggling with costs:

Novo Nordisk Programs:

• Savings Card (for commercially insured patients): Reduces Wegovy copays to as low as $0 per month (maximum savings of $225/month) for up to 24 months
• Wegovy Access (cash-pay program): Self-pay price reduced to $349/month at retail pharmacies (down from ~$1,350 list price)
• Patient Assistance Program: Free medication for uninsured or underinsured patients who meet income requirements (typically <400% federal poverty level)

Eli Lilly Programs:

• Mounjaro Savings Card: $25 per month for commercially insured diabetes patients (covers up to ~$500 in costs)
• LillyDirect: Zepbound single-dose vials now $299–$449/month depending on dose (significantly less than the ~$1,080 list price)
• Patient Assistance Program: Free or reduced-cost medication for qualifying low-income patients

Important Restriction: Manufacturer copay cards cannot be used with government insurance (Medicare, Medicaid, TRICARE). They’re designed for commercial insurance or self-pay patients only.

GoodRx and Discount Programs

In November 2025, GoodRx launched an innovative partnership with Novo Nordisk offering unprecedented access:

GoodRx Weight Loss Program:

• $199/month for the first two months of Wegovy or Ozempic
• $349/month ongoing for most maintenance doses
• Available at nearly all major U.S. pharmacies nationwide
• No insurance required—straightforward cash pricing
• Represents approximately 70% savings off list prices

This program makes GLP-1s accessible to many patients who previously couldn’t afford them, even without insurance coverage. The $39/month GoodRx telemedicine subscription provides comprehensive weight management support, with the medication pricing separate but significantly reduced.

Standard GoodRx Coupons:Even without the special program, GoodRx coupons can reduce costs:

• Ozempic: ~$800–$900/month (vs. $998 list)
• Mounjaro: ~$1,000/month (vs. $1,080 list)
• Wegovy: ~$1,100/month (vs. $1,350 list)

Alternative Options to Consider

Older Weight-Loss Medications:If GLP-1s remain unaffordable, FDA-approved alternatives include:

• Phentermine (generic): $30–$50/month
• Orlistat (Alli, generic): $50–$100/month
• Contrave (naltrexone-bupropion): $100–$250/month
• Qsymia (phentermine-topiramate): $150–$200/month with discounts

While these aren’t as effective as GLP-1s for most patients, they’re substantially more affordable and may be stepping stones toward GLP-1 approval.

Compounded Medications:Some telehealth services and compounding pharmacies offer semaglutide or tirzepatide at lower prices ($200–$400/month). Exercise caution: these are not FDA-approved formulations. The FDA has warned about quality, potency, and safety concerns with compounded GLP-1s. They may be appropriate in certain circumstances, but discuss risks thoroughly with your healthcare provider.

How Klarity Health Can Help Navigate Your Coverage Journey

At Klarity Health, we understand that medication coverage shouldn’t be a barrier to effective weight management. Our approach simplifies the process:

Transparent Pricing:We accept both insurance and cash pay, with clear, upfront pricing so you know exactly what to expect. No surprise bills or hidden fees.

Provider Availability:Connect with experienced healthcare providers via telehealth who understand both the clinical side of GLP-1 therapy and the insurance landscape. Our providers can help document medical necessity, complete prior authorizations, and advocate for coverage.

Insurance Navigation Support:Our team can verify your coverage, help you understand your benefits, and guide you through the PA process. If your insurance denies coverage, we’ll help you explore manufacturer programs, discount options, and alternatives.

Flexible Treatment Plans:Whether you have comprehensive insurance coverage, limited benefits, or are paying out-of-pocket, we work with you to design an affordable, effective treatment plan. We’ll help you access manufacturer savings programs and identify the most cost-effective pathway to your weight-management goals.

Is Telehealth for Weight Loss Covered by Insurance?

Great news: telehealth visits for weight management are generally covered by most insurance plans as of 2025. The pandemic accelerated telehealth adoption, and over 40 states now have parity laws requiring insurers to cover virtual care equivalently to in-person visits.

What This Means:

• If your plan covers obesity counseling or medical weight management in-person, it should cover telehealth visits at the same copay
• Nutritional counseling for obesity is an ACA-mandated preventive service, often covered at 100% when done via telehealth
• Medicare and most commercial plans cover telehealth consultations for weight management

Considerations:

• Use in-network providers when possible (verify Klarity Health’s network status with your plan)
• Most insurers require live video (not just phone or messaging) for full reimbursement
• The visit may be covered even if the medication isn’t—meaning you can get affordable telehealth care while using manufacturer programs or cash-pay for prescriptions

This dual approach—insurance-covered telehealth consultations combined with manufacturer programs for medication—creates an accessible pathway for many patients.

Making Your Decision: Key Takeaways

Before pursuing GLP-1 medication:

1. Check your specific insurance formulary and coverage documents—don’t rely on assumptions
2. Understand your diagnosis matters: Diabetes patients generally get easier coverage than those seeking weight loss alone
3. Gather documentation early: Six months of supervised weight-loss attempts, BMI records, comorbidity documentation
4. Be prepared for prior authorization: It’s standard, not personal—work with your provider to submit complete information
5. Know your appeal rights: Initial denials don’t have to be final if you meet clinical criteria
6. Explore all financial assistance: Manufacturer programs, GoodRx partnerships, and patient assistance can dramatically reduce costs

If you’re denied coverage:

• Don’t assume it’s permanent—many denials are overturned with proper documentation
• Ask your provider to submit a letter of medical necessity
• Consider alternative approaches (different medication, different diagnosis documentation)
• Explore self-pay options—2025 pricing programs make these drugs more accessible than ever

Work with providers who understand the system:The difference between coverage approval and denial often comes down to documentation quality and persistence. Experienced providers who regularly prescribe these medications (like those at Klarity Health) know how to navigate PA requirements and maximize your chances of approval.

Weight management is a legitimate medical concern, and effective treatments exist. Whether through insurance coverage, manufacturer programs, or affordable self-pay options, there’s likely a pathway that works for your situation. The key is understanding your options, being persistent, and partnering with providers who can help you navigate the system.

Ready to explore your weight-management options? Connect with Klarity Health to discuss your insurance coverage, financial assistance programs, and personalized treatment plans that fit your needs and budget.

FAQ: Common Questions About GLP-1 Insurance Coverage

Q: Can I use my insurance for Ozempic if I don’t have diabetes but want to lose weight?

A: Probably not. Most insurance plans only cover Ozempic for its FDA-approved indication (Type 2 diabetes). If prescribed off-label for weight loss, expect a denial. Wegovy (same medication, different FDA approval) is the appropriate prescription for weight management, though it faces different coverage hurdles.

Q: How long does prior authorization take?

A: Initial PA decisions typically take 5-7 business days, though some insurers respond within 24-72 hours for urgent requests. Appeals can take 2-3 weeks. Plan ahead and don’t wait until the last minute to request authorization.

Q: Will my insurance cover both the doctor visits and the medication?

A: Possibly both, possibly just one. Telehealth visits for weight management are widely covered, but medication coverage is much more variable. You might have covered visits while paying out-of-pocket for medication (using manufacturer programs or GoodRx discounts).

Q: What’s the difference between a manufacturer coupon and a patient assistance program?

A: Coupons/savings cards reduce your copay when you have commercial insurance coverage (or offer discounted cash prices). They’re generally available to anyone with private insurance regardless of income. Patient assistance programs provide free or low-cost medication to uninsured or underinsured patients who meet financial need criteria (income limits apply).

Q: Can I switch from Ozempic to Wegovy if my insurance covers one but not the other?

A: They’re the same active ingredient (semaglutide), but insurers treat them as different drugs based on FDA approval. If your insurance covers Ozempic for diabetes but won’t cover Wegovy for weight loss, your provider can’t simply switch the prescription—the coverage is tied to your diagnosis and the drug’s labeled indication.

Q: Are there any states where Medicaid reliably covers weight-loss medications?

A: As of 2025, very few—and the number is shrinking. New York continues to cover with PA requirements. Some states like Louisiana and Minnesota maintain limited coverage. However, California and Pennsylvania are eliminating coverage in January 2026. Always verify current policy in your specific state, as this landscape changes frequently.

Q: What happens if I lose weight successfully and my insurance stops covering the medication?

A: This is a common concern. Most clinical guidelines and insurance policies recognize obesity as a chronic condition requiring ongoing management. If you’ve achieved weight loss and maintain medical necessity (ongoing obesity or comorbidities), continued coverage should be possible. However, some plans time-limit obesity medication coverage (e.g., 12-24 months maximum). Discuss long-term plans with your provider early.

Q: Is compounded semaglutide a good alternative if insurance won’t cover brand-name drugs?

A: Approach with caution. Compounded versions aren’t FDA-approved, may have quality/potency variability, and carry potential safety risks. The FDA has issued warnings about compounded GLP-1s. They’re sometimes appropriate as a short-term option or when brand medications are unavailable (like during shortages), but discuss thoroughly with your provider. The 2025 manufacturer price reductions and GoodRx programs make brand-name options more competitive with compounded alternatives.

📅 RESEARCH CURRENCY STATEMENT (Verified as of December 17, 2025)

Formularies checked: Aetna Clinical Policy (May 2024) (www.aetna.com); Cigna Formulary (April 2024) (www.singlecare.com); Kaiser Permanente update (January 2025) (www.amwinsconnect.com); Texas VDP criteria (March 2023) (www.texaschildrenshealthplan.org); Pennsylvania Medicaid bulletin (August 2024) (www.phlp.org).

Medicaid formularies verified: California DHCS (December 2025) (www.cmadocs.org); Texas HHSC (March 2023) (www.texaschildrenshealthplan.org); Florida (no Medicaid coverage per federal exclusion (www.texaschildrenshealthplan.org)); New York NYRx PDL (October 2025) (solutionshortcut.com); Pennsylvania DHS (December 2025) (www.cmadocs.org); Illinois HFS (no coverage as of 2025) (www.forbes.com).

GoodRx prices as of: December 2025 – Novo Nordisk/NovoCare program (effective November 2025) (www.fiercepharma.com); GoodRx press release (November 17, 2025) (www.businesswire.com); Lilly pricing updates (December 2025) (www.fiercepharma.com).

Coverage status and pricing are accurate as of December 17, 2025. Insurance policies and formularies can change with new plan years—always verify current information with your specific insurance plan or healthcare provider.

Source:

• https://www.aetna.com/products/rxnonmedicare/data/2024/WeightLoss%28BMI%2035%29GIP-GLP-1GLP-1AgonistsPAwithLimit6450-CUDR_05-2024.html#:~:text=%C2%B0Wegovy%3A%20Initial%20therapy%20DOA%3A%207,based%20on%20the%20following%20references
• https://www.singlecare.com/blog/cigna-prior-authorization-weight-loss/#:~:text=Cigna%20coverage%20criteria%20for%20GLP,drugs
• https://www.amwinsconnect.com/news/kaiser-permanenter-coverage-changes-glp-1-drugs-and-anti-obesity-medications-2025#:~:text=drugs%20and%20other%20AOMs%20will,with%20BMI%20less%20than%2040
• https://www.texaschildrenshealthplan.org/2023/04/28/provider-alert-non-formulary-requests-for-obesity-control-drugs#:~:text=for%20obesity%20control%20drugs%20for,Imcivree%2C%20Qysmia%2C%20Saxenda%20and%20Wegovy
• https://www.phlp.org/en/news/pennsylvania-medicaid-covers-newer-weight-loss-drugs#:~:text=Generally%2C%20to%20get%20these%20drugs,CDC%29%20charts
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=What%20You%20Need%20to%20Know%3A,Cal%20managed%20care
• https://solutionshortcut.com/medicaid-drug-coverage-by-state-2025-2026-updates/#:~:text=VDP%20PDL%20%26%20criteria%3B%20last,com
• https://www.cmadocs.org/newsroom/news/view/ArticleId/51074/GLP-1-medications-for-weight-loss-will-no-longer-be-covered-by-Medi-Cal#:~:text=%2A%20Three%20GLP,covered%20after%20January%201%2C%202026
• https://www.forbes.com/sites/joshuacohen/2025/08/07/coverage-of-weight-loss-drugs-by-medicaid-plans-continues-to-lag/#:~:text=Medicaid%2C%20a%20federal,employees%20due%20to%20cost%20concerns
• https://www.fiercepharma.com/marketing/novo-unveils-newly-reduced-self-pay-prices-wegovy-ozempic-after-white-house-deal#:~:text=Novo%20revealed%20Monday%20that%20the,will%20still%20run%20for%20%24499